1. AUGMENT PHASE III STUDY: LENALIDOMIDE/RITUXIMAB (R2) IMPROVED EFFICACY OVER RITUXIMAB/PLACEBO IN RELAPSED/REFRACTORY FOLLICULAR PATIENTS IRRESPECTIVE OF POD24 STATUS. (12th June 2019) Authors: Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Gribben, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 114 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. AUGMENT: RELAPSED/REFRACTORY INDOLENT NHL PATIENTS WERE MORE SENSITIVE TO NEXT TREATMENT FOLLOWING LENALIDOMIDE/RITUXIMAB (R2) THAN RITUXIMAB/PLACEBO. (12th June 2019) Authors: Gribben, J.; Trneny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C.; Leonard, J. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 227 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. HEALTH‐RELATED QUALITY OF LIFE (HRQoL) IN RELAPSED/REFRACTORY (R/R) INDOLENT NHL IN THE PHASE 3 AUGMENT TRIAL OF RITUXIMAB (R) PLUS LENALIDOMIDE (R2) VERSUS R PLUS PLACEBO. (12th June 2019) Authors: Leonard, J.P.; Trněny, M.; Izutsu, K.; Fowler, N.H.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.M.; Scheinberg, P.; Flinn, I.W.; Moreira, C.; Tabah, A.; Abouzaid, S.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 232 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. POST HOC ANALYSES OF PATIENTS WITH RELAPSED/REFRACTORY MARGINAL ZONE LYMPHOMA WHO RECEIVED LENALIDOMIDE PLUS RITUXIMAB (R2) VS RITUXIMAB/PLACEBO (AUGMENT). (12th June 2019) Authors: Thieblemont, C.; Leonard, J.; Trneny, M.; Izutsu, K.; Fowler, N.; Hong, X.; Zhang, H.; Offner, F.; Scheliga, A.; Nowakowski, G.; Pinto, A.; Re, F.; Fogliatto, L.; Scheinberg, P.; Flinn, I.; Moreira, C.; Czuczman, M.; Kalambakas, S.; Fustier, P.; Wu, C. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 226 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗